We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Cardinal Health (CAH - Free Report) closed at $161.98, marking a -1.47% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.48%. Elsewhere, the Dow saw a downswing of 0.02%, while the tech-heavy Nasdaq appreciated by 0.94%.
Shares of the prescription drug distributor have appreciated by 5.74% over the course of the past month, outperforming the Medical sector's gain of 2.8%, and the S&P 500's gain of 5.13%.
Investors will be eagerly watching for the performance of Cardinal Health in its upcoming earnings disclosure. The company is forecasted to report an EPS of $2.02, showcasing a 9.78% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $60.65 billion, up 1.31% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.18 per share and revenue of $223.07 billion, indicating changes of +8.63% and 0%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Cardinal Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.1% higher within the past month. Cardinal Health is currently a Zacks Rank #2 (Buy).
Investors should also note Cardinal Health's current valuation metrics, including its Forward P/E ratio of 17.89. Its industry sports an average Forward P/E of 17.95, so one might conclude that Cardinal Health is trading at a discount comparatively.
It's also important to note that CAH currently trades at a PEG ratio of 1.64. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.68 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 23, finds itself in the top 10% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Cardinal Health (CAH - Free Report) closed at $161.98, marking a -1.47% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.48%. Elsewhere, the Dow saw a downswing of 0.02%, while the tech-heavy Nasdaq appreciated by 0.94%.
Shares of the prescription drug distributor have appreciated by 5.74% over the course of the past month, outperforming the Medical sector's gain of 2.8%, and the S&P 500's gain of 5.13%.
Investors will be eagerly watching for the performance of Cardinal Health in its upcoming earnings disclosure. The company is forecasted to report an EPS of $2.02, showcasing a 9.78% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $60.65 billion, up 1.31% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.18 per share and revenue of $223.07 billion, indicating changes of +8.63% and 0%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Cardinal Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.1% higher within the past month. Cardinal Health is currently a Zacks Rank #2 (Buy).
Investors should also note Cardinal Health's current valuation metrics, including its Forward P/E ratio of 17.89. Its industry sports an average Forward P/E of 17.95, so one might conclude that Cardinal Health is trading at a discount comparatively.
It's also important to note that CAH currently trades at a PEG ratio of 1.64. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.68 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 23, finds itself in the top 10% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.